Editas Medicine Co-Founders Present Novel Methods For Improving Genome Editing Specificity In Two Nature Biotechnology Papers
4/28/2014 8:57:23 AM
Editas Medicine, a transformative genome editing company, today announced the publication of new data highlighting novel approaches to improve the specificity of CRISPR/Cas9 genome editing technology. The data are presented in two papers independently co-authored by company co-founders Keith Joung, M.D., Ph.D. and David Liu, Ph.D. in the current online edition of Nature Biotechnology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by